Menu
PacPremier
Magic Hour
Montecito
SoCal Gas
Loading...
You are here:  Home  >  'Humira'
Latest

Amgen launches Humira biosimilar in Europe

By   /  Tuesday, October 16th, 2018  /  Central Coast Health Watch, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Amgen launches Humira biosimilar in Europe

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen settles with AbbVie over Humira biosimilar litigation

By   /  Friday, October 6th, 2017  /  Central Coast Health Watch, East Ventura County, right, Technology  /  Comments Off on Amgen settles with AbbVie over Humira biosimilar litigation

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen settles with AbbVie over Humira biosimilar

By   /  Thursday, September 28th, 2017  /  Central Coast Health Watch, East Ventura County, Latest news, Technology  /  Comments Off on Amgen settles with AbbVie over Humira biosimilar

Thousand Oaks biopharmaceutical giant Amgen announced Sept. 28 that it had reached a settlement with Chicago-based competitor AbbVie, which had sued to block Amgen’s Humira biosimilar Amjevita. The rheumatoid arthritis and inflammation treatment received U.S. Food and Drug Administration approval in September of 2016, but sales were blocked when AbbVie filed a patent infringement claim Read More →

Read More →
Latest

Amgen’s Kyprolis found to increase cancer survival rate

By   /  Thursday, July 13th, 2017  /  Central Coast Health Watch, East Ventura County, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Amgen’s Kyprolis found to increase cancer survival rate

A Phase 3 clinical study of Amgen’s multiple myeloma drug Kyprolis showed that it increased overall survival rate when paired with lenalidomide and dexamethasone versus just those two drugs alone. The drug reduced the risk of death by 21 percent, and patients lived 7.9 months longer when on a regimen that included Kyprolis than those Read More →

Read More →
Latest

Amgen gets European approval for biosimilar of Humira

By   /  Friday, March 24th, 2017  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen gets European approval for biosimilar of Humira

Thousand Oaks-based Amgen has announced that the European Commission has granted marketing authorization for Amgevita, a drug that treats inflammatory diseases, including moderate-to-severe rheumatoid arthritis. The Amgen biosimilar will compete with AbbVie’s blockbuster drug Humira. “The approval of our first biosimilar by the European Commission is a major milestone not just for Amgen as a company, but for the millions Read More →

Read More →
Latest

Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira

By   /  Friday, January 27th, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Europeans recommend approval of Amgen’s biosimilar of AbbVie’s Humira

The European Medicines Agency recommended the approval of the ABP 501, a biosimilar of AbbVie’s Humira (adalimumab), for treatment of inflammatory diseases, Thousand Oaks-based biotech company Amgen announced on Jan. 27. The EMA recommended ABP 501’s use for moderate-to-severe rheumatoid arthritis, psoriatic arthritis, severe ankylosing spondylitis, severe axial spondyloarthritis without radiographic evidence of AS, moderate-to-severe Read More →

Read More →
Latest

Amgen’s Humira biosimilar delayed, Enbrel approved

By   /  Thursday, November 10th, 2016  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Amgen’s Humira biosimilar delayed, Enbrel approved

Amgen’s Humira biosimilar Amjevita will be delayed at least through 2017 due to litigation by competitor AbbVie. The maker of Humira filed a patent infringement claim against Amgen on Aug. 4, alleging that the drug also violates the Biosimilar Price Competition and Innovation Act. Amgen was approved to market its biosimilar Sept. 23 by the Read More →

Read More →